<DOC>
	<DOC>NCT01306890</DOC>
	<brief_summary>The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.</brief_summary>
	<brief_title>A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer</brief_title>
	<detailed_description>Subjects will receive product as described in the sipuleucel-T approved label. The registry will be strictly observational and thus no additional clinical visits or laboratory tests will be conducted beyond normal clinical practice. Investigators will be asked to record information that becomes available in the normal course of clinical management.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>subjects must be at least 18 years of age subjects with advanced prostate cancer who will receive sipuleucelT or who underwent their first leukapheresis for manufacture of sipuleucelT ≤ 6 months prior to enrollment subjects must understand and sign an informed consent form</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>